Back

From access to action in transthyretin amyloid cardiomyopathy: are we missing opportunities for therapy optimization?

European Journal of Heart Failure

20 July 2026
Organised by: Logo
Read full article
ESC Journals HEART FAILURE Chronic Heart Failure

Contributors

Daniela Tomasoni
Daniela Tomasoni

Author

Spedali Civili, University Of Brescia Brescia , Italy

Alberto Aimo
Alberto Aimo

Author

Marianna Fontana
Marianna Fontana

Author

You may be interested in
thumbnail
Congress Session
ACT FAST for ATTR-CM: early clues in heart failure to raise clinical suspicion
17 May 2025
thumbnail
Congress Presentation
Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
27 August 2022
thumbnail
Congress Presentation
Discussant review - CARDIO-TTRansform
28 August 2026
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025

ESC 365 is supported by

Lilly Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources